XXXX : assessment of in vivo clastogenicity and carcinogenicity.

@entity2008 @entity5 @entity3794 @entity35 @entity236 @entity1499
The genotoxic and oncogenic potentials of @entity1499 were studied in @entity35 . The @entity35 received 0.1, 0.2, or 0.4 mg/kg of @entity1499 as dietary admixtures on a 5 days on, 9 days off, regimen for 23 months. In the females of the high-dose group, there was a significant increase in mortality starting at 18 months. Significant increases in the number of @entity35 with focal @entity3794 were seen in both sexes at the high-dose level. At the mid- and high-dose levels of both sexes, there was a significantly increased number of @entity35 with myeloid and erythroid @entity236 . There was no evidence of either early onset or increased incidence of any @entity5 type in the treatment groups. Therefore, it is concluded that @entity1499 does not have oncogenic potential. Also, at terminal sacrifice, bone marrow cells were harvested from selected animals on the last day of the 5-day dosing cycle and cytogenetic evaluation was performed. No significant @entity2008 was seen in any dose group relative to the control group. This observation further substantiates the absence of oncogenic potential due to @entity1499 in @entity35 .
